Clinical trials: Alcoholic Liver Disease
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
The purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others.
- Conditions
- Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity
- Trial name
- NCT01104220
- Testing
- Weight loss
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type2 Diabetes, NAFLD
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes. Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown to reduce production and deposition of fat in the…
- Trial name
- NCT02964715
- Testing
- Empagliflozin
- Where
- Malaysia
- Volunteers
- 25 people
- Sponsor
- University of Malaya
Non-alcoholic Steatohepatitis
Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis
This study evaluates the dietary and therapeutic effect of supplement consisting of sublimated mare milk among patients with non-alcoholic steatohepatitis.
- Trial name
- NCT03664596
- Testing
- Sublimated mare's milk, Ursodeoxycholic Acid
- Where
- Kazakhstan
- Volunteers
- 80 people
- Sponsor
- Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan
Liver Cirrhosis
Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics
The study will be conducted in department of Hepatology at ILBS, the patients will be recruited from the OPD or IPD . The obese cirrhotic patients with NASH will be observed for standard of care and also patients who undergo IGB…
- Trial name
- NCT03753438
- Testing
- Intragstric Ballooning
- Where
- India
- Volunteers
- 56 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Metabolic Syndrome
- Trial name
- Aramchol003 (NCT01094158)
- Testing
- Aramchol
- Where
- 11 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Galmed Medical Reserch
Non Alcoholic Fatty Liver
Oral Dietary Fucoxanthin Rich Supplement for Liver Health
Blind, placebo-controlled study testing the hypothesis that oral dietary supplement rich with fucoxanthin will decrease biochemical clinical markers related to liver health.
- Trial name
- NCT03625284
- Testing
- FucoVital
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Algatechnologies Ltd.
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
Fatty Liver, Liver Fibrosis
Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- EDACN (NCT00885313)
- Testing
- DHA250, DHA500, Lifestyle intervention
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
- Trial name
- NCT05728697
- Testing
- Endoscopic ultrasound shear wave elastography
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Brigham and Women's Hospital
Liver Diseases, Alcoholic
Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population
This is a pilot study examining whether an evidence-based recovery support smartphone application, the Addiction Comprehensive Health Enhancement Support System (A-CHESS), can decrease alcohol recidivism in a previously unstudied…
- Trial name
- NCT03388320
- Testing
- A-CHESS
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York Presbyterian Hospital
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease
- Trial name
- NCT06465186
- Testing
- Efinopegdutide
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Alcoholic Steatohepatitis (NASH)
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04140123
- Testing
- ZSP1601
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
NAFLD
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
- Trial name
- NCT03744182
- Testing
- HM15211
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Liver Diseases, Alcoholic, Alcohol Use Disorder
Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial
To evaluate the efficacy of systematically offering newly diagnosed ALD patients to AUD treatment, in the hepatology clinic, on alcohol abstinence after 6 months.
- Conditions
- Liver Diseases, Alcoholic, Alcohol Use Disorder, Treatment Adherence, Alcoholism
- Trial name
- NCT06493773
- Testing
- Offer of specialized alcohol use disorder treatment in the hepatology clinic
- Where
- Denmark
- Volunteers
- 221 people
- Sponsor
- Zealand University Hospital
Non-alcoholic Fatty Liver Disease
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver.
- Trial name
- NCT02006498
- Testing
- Sillymarin
- Where
- Malaysia
- Volunteers
- 99 people
- Sponsor
- University of Malaya
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Affecting approximately one-third of the United States (U.S.) population, the prevalence of NAFLD increases to 90% in patients with…
- Conditions
- Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound
- Trial name
- NCT04820036
- Testing
- Insulin Resistance, Quality of Life Assessment, Liver Function Test
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Non-Alcoholic Steatohepatitis
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
- Trial name
- NCT02571192
- Testing
- SHP626, 5.95 μCi RAD
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Alcoholic Hepatitis (AH)
Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH).
- Trial name
- NCT02854631
- Testing
- Selonsertib, Prednisolone
- Where
- 44 sites in United States, Austria and 5 more
- Volunteers
- 104 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Steatohepatitis(NASH)
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity.
- Trial name
- NCT00706537
- Testing
- Active treatment
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or…
- Trial name
- NCT04235205
- Testing
- Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
- Where
- Japan
- Volunteers
- 102 people
- Sponsor
- Yokohama City University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.